drugset / Trial / NCT02815657

The Drug-drug Interaction of SP2086 and Valsartan

NCT02815657

Phase 1 Completed 16 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to investigate the potential interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy adult volunteers.

Timeline

Start
2013-04
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Retagliptin Small molecule 200 mg Oral
Comparator Valsartan Small molecule 160 mg